Literature DB >> 7913624

Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein.

A Shirai1, M Naito, T Tatsuta, J Dong, K Hanaoka, K Mikami, T Oh-hara, T Tsuruo.   

Abstract

P-glycoprotein, a multidrug transporter protein, exists in the brain capillary endothelium. To study the function of P-glycoprotein in brain capillary endothelium as a barrier against cyclosporin A, we examined the interaction of cyclosporin A with P-glycoprotein expressed in cultured brain capillary endothelial cells (MBEC4). P-glycoprotein of MBEC4 specifically bound [125I]iodoaryl azidoprazosin, and the binding was inhibited by cyclosporin A and vincristine. Intracellular accumulation of cyclosporin A in MBEC4 was about one-third the amount accumulated in mouse aortic endothelial cells (MAEC3), a cell line that did not express P-glycoprotein. The reduced accumulation of cyclosporin A in MBEC4 was increased by verapamil, a competitive inhibitor of transport function of P-glycoprotein. Cyclosporin A was preferentially transported from basal to apical side when the cell monolayer of MBEC4 was formed; however this transendothelial transport was not observed across cell monolayer of MAEC3. Verapamil inhibited the transendothelial transport of cyclosporin A across the MBEC4 monolayer. Thus P-glycoprotein in brain capillary endothelium could transport cyclosporin A across the endothelium from the basal to the apical side. These observations suggest that P-glycoprotein is involved in the complex function of the blood-brain barrier as a secretory detoxifying transporter of cyclosporin A.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7913624     DOI: 10.1016/0167-4889(94)90047-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Inhibition of P-glycoprotein: rapid assessment of its implication in blood-brain barrier integrity and drug transport to the brain by an in vitro model of the blood-brain barrier.

Authors:  L Fenart; V Buée-Scherrer; L Descamps; C Duhem; M G Poullain; R Cecchelli; M P Dehouck
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

Review 2.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Physiologically based pharmacokinetics of cyclosporine A: reevaluation of dose-nonlinear kinetics in rats.

Authors:  C Tanaka; R Kawai; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1999-12

4.  P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain.

Authors:  E Beaulieu; M Demeule; L Ghitescu; R Béliveau
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

5.  Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats.

Authors:  C S Hughes; S L Vaden; C A Manaugh; G S Price; L C Hudson
Journal:  J Neurooncol       Date:  1998-03       Impact factor: 4.130

6.  P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier.

Authors:  T Miyama; H Takanaga; H Matsuo; K Yamano; K Yamamoto; T Iga; M Naito; T Tsuruo; H Ishizuka; Y Kawahara; Y Sawada
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

7.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

Authors:  A H Schinkel; E Wagenaar; L van Deemter; C A Mol; P Borst
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.